IMARC Group has recently released a new research study titled “United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region, 2026-2034”, offering a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

United States Biologics Market Size & Share 2026-2034

The United States biologics market size was valued at USD 204.4 Billion in 2025 and is projected to reach USD 386.2 Billion by 2034, expanding at a CAGR of 7.11% during 2026-2034. The market is primarily driven by the rapid adoption of bioprocessing technologies for efficiency, growing expansion of biosimilars addressing affordability, and rising AI integration in drug discovery, clinical trials, and manufacturing.

According to the CDC, an estimated 129 Million Americans have at least one chronic disease, with 42% managing two or more and 12% dealing with at least five conditions, and chronic diseases account for 90% of the annual USD 4.1 Trillion healthcare expenditure, highlighting the need for innovative biologics. Growing investments in research and development by biotech and pharmaceutical firms, alongside supportive FDA frameworks such as fast-track approvals, are expected to strengthen the United States biologics market share throughout the forecast period.

Key Market Statistics at a Glance

• Base Year: 2025
• Historical Years: 2020-2025
• Forecast Period: 2026-2034
• Market Size (2025): USD 204.4 Billion
• Projected Market Size (2034): USD 386.2 Billion
• Growth Rate: CAGR of 7.11% (2026-2034)

Explore Opportunities in the United States Biologics Market: Download the IMARC Sample Report: https://www.imarcgroup.com/united-states-biologics-market/requestsample

Key Growth Drivers and Trends in the United States Biologics Market

Growth in the United States biologics market is being driven by growing adoption of advanced bioprocessing technologies, thus leading to highly improved efficiency in production and scalability. Technologies such as single-use bioreactors, continuous manufacturing, and high-throughput screening systems are streamlining manufacturing processes. Rentschler Biopharma’s Milford facility, operational since July 11, 2024, with four 2,000L single-use bioreactors, doubled cGMP capacity for complex biologics, supporting innovative therapies and global healthcare advancements while reducing production costs and enhancing biologics’ accessibility.

One of the leading United States biologics market trends is the rapid expansion of the biosimilars segment given growing demand for affordable alternatives to branded biologics. The FDA’s Biosimilar Approval Pathway has allowed easier market entry and increased competition while decreasing treatment costs, making biologic therapies more accessible for chronic diseases like cancer and autoimmune disorders. On July 2, 2024, Sobi began a rolling BLA submission for SEL-212, a novel biologic aimed at serum urate levels in chronic refractory gout, reflecting continued pharmaceutical investment in biosimilar research and development as patents for existing biologics expire.

Another key factor supporting United States biologics market growth is the ongoing integration of artificial intelligence in biologics development, speeding up drug discovery, optimizing clinical trials, and enhancing production processes. AI-powered platforms analyze enormous datasets to identify promising biologic candidates, cutting down time and cost involved in traditional R&D, while streamlining patient recruitment, monitoring real-time data, and predicting outcomes in clinical trials. On May 15, 2024, Galapagos NV and Blood Centers of America announced a partnership decentralizing CAR-T therapy manufacturing across 50 U.S. centers to ensure rapid seven-day vein-to-vein delivery and enhance scalability, physician control, and patient access.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

United States Biologics Industry Segmentation Insights

Breakup by Source:

• Microbial: Serves as an efficient host system for producing recombinant proteins, enzymes, and vaccines, with E. coli and yeast systems commonly employed for high-yield, cost-effective, and scalable manufacturing.
• Mammalian: Critical for producing complex biologics such as monoclonal antibodies, fusion proteins, and cell therapies, with CHO cells dominating this segment given their superior post-translational modifications and bioactivity.
• Others: Includes additional biologic source systems supporting specialized production needs.

Breakup by Product:

• Monoclonal Antibodies: Represents a mainstay of the market, used widely for cancer, autoimmune diseases, and infections, with continued innovation in antibody-drug conjugates and bispecific antibodies.
• Vaccines: Growing at an impressive rate, driven by advancements in mRNA technology, pandemic preparedness, and expanding research into cancer and personalized vaccines.
• Recombinant Proteins: Widely used in treating diabetes, anemia, and growth disorders, with innovations in protein engineering enhancing therapeutic efficacy and stability.
• Antisense, RNAi and Molecular Therapy: Represents an advancing therapeutic category leveraging molecular mechanisms to target disease at the genetic level.
• Others: Includes additional biologic product categories serving specialized therapeutic needs.

Breakup by Disease:

• Oncology: Leads the market given the significant occurrence of cancer and rising need for targeted treatments, with monoclonal antibodies and immune checkpoint inhibitors transforming cancer therapy.
• Immunological Disorders: Witnessing strong growth with rising incidence of diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease managed through cytokine inhibitors and TNF blockers.
• Cardiovascular Disorders: Gaining ground through innovative treatments such as PCSK9 inhibitors for cholesterol regulation and growth in regenerative therapies.
• Hematological Disorders: Represents a significant application area for biologic therapies addressing blood-related conditions.
• Others: Includes additional disease categories benefiting from biologic therapy development.

Breakup by Manufacturing:

• Outsourced: Increasing as companies rely on contract research and manufacturing organizations for effective, cost-efficient production, freeing up processes and providing access to sophisticated, scalable facilities.
• In-House: Remains vital for companies prioritizing control over manufacturing processes, quality assurance, and intellectual property, particularly for high-value biologics like monoclonal antibodies and cell therapies.

Breakup by Region:

• Northeast: Driven by a concentration of leading biotechnology and pharmaceutical companies, particularly in Massachusetts and New York, supported by robust R&D infrastructure and academic collaborations.
• Midwest: Growing rapidly in biologics manufacturing, with significant contributions from Illinois and Indiana supported by an established pharmaceutical manufacturing base and government incentives.
• South: Benefits from major biopharmaceutical companies and favorable business climates in states like North Carolina and Texas, alongside increasing clinical trial and biotechnology research activity.
• West: Dominates biologics innovation, particularly in California, home to Silicon Valley’s biotechnology companies and strong venture capital funding for CAR-T cell therapies and mRNA vaccines.

Key Challenges and Growth Opportunities in the United States Biologics Market

The United States biologics market faces challenges including high manufacturing costs associated with complex biologic production, particularly for mammalian cell-based therapies, along with the technical complexity of scaling advanced bioprocessing technologies. Ensuring consistent quality and regulatory compliance across increasingly complex biologic modalities also remains an ongoing consideration for manufacturers.

Despite these challenges, the market offers considerable growth opportunities driven by expanding biosimilar adoption addressing affordability, growing integration of AI across drug discovery and manufacturing, and rising healthcare expenditure with positive reimbursement policy increasing patient access to biologic therapies. Continued advancement of personalized medicine addressing complex medical needs is expected to create substantial opportunities for long-term growth in the United States biologics market.

Competitive Landscape

Competition in the United States biologics market comes through key pharmaceutical and biotech innovators, which continue investing heavily in R&D activities. Major players boast advanced portfolios for next-generation monoclonal antibodies, vaccines, and gene therapies, while emerging startups and contract research organizations contribute niche biologics development and outsourcing solutions. Strategic partnerships and acquisitions often serve as primary market-positioning strategies, while advances in manufacturing technologies and personalized medicine continuously reshape the competitive landscape of this rapidly growing market.

Recent Developments in the United States Biologics Market

• September 27, 2024: The FDA approved Dupixent (dupilumab) as the first biologic for inadequately controlled COPD with an eosinophilic phenotype, with Phase 3 trials showing exacerbation reductions of up to 34% and improved lung function.
• February 29, 2024: Biocon Biologics Ltd signed a settlement and license agreement with Janssen Biotech to commercialize Bmab 1200, a biosimilar to Stelara, in the U.S. starting February 2025 pending FDA approval, resolving a patent dispute and supporting Biocon’s immunology franchise expansion.

Author IMARC Group

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multidisciplinary team of industry experts, IMARC delivers reliable market intelligence across sectors including Chemicals and Materials, Healthcare, Technology, Agriculture, and Retail.

Contact Us:

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302